[Rebound hypercalcemia after denosumab therapy in a 13-year-old boy with an aneurysmal bone cyst of the humerus-a case report].

Beatrice Jung, Frank Traub, Tilmann Busse, Eren Demir

Abstract readCase ReportsEnglish Abstract

In one paragraph

Article in Orthopadie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Beatrice JungZentrum für Orthopädie und Unfallchirurgie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland. Beatrice.Jung@unimedizin-mainz.de.

Frank TraubZentrum für Orthopädie und Unfallchirurgie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.

Tilmann BusseZentrum für Orthopädie und Unfallchirurgie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.

Eren DemirZentrum für Orthopädie und Unfallchirurgie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denosumab is approved for the treatment of osteoporosis and selected bone tumors, with its efficacy well documented in the literature. However, its use in children for benign bone tumors remains off-label. We report the case of a 13-year-old boy with an aneurysmal bone cyst of the humerus who developed severe hypercalcemia following the cessation of supportive denosumab therapy. The patient was successfully treated with intravenous fluid therapy, potassium supplementation, zoledronate, and furosemide. This case highlights the necessity for close monitoring of calcium and bone metabolism in children and adolescents during and after denosumab treatment.

Indexed as

Bone Cysts, AneurysmalBone Density Conservation AgentsDenosumabHumerusHypercalcemiaAdolescentHumansMaleTreatment OutcomeBone Density Conservation AgentsDenosumabBone neoplasmsChildrenDietary calciumHumerusOff-label use

Identifiers

PMID41288655

DOI10.1007/s00132-025-04745-1

PMCPMC13013244

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.